Shares of FMCG and Ayurvedic major Dabur India have slid into the spotlight after the United States Food and Drug Administration (US FDA) slapped a formal import alert on drug products manufactured at its Silvassa facility in Dadra and Nagar Haveli. The regulatory mandate, categorized under Import Alert 66-40, enforces a “Detention Without Physical Examination” status, allowing US port authorities to automatically block and seize incoming consignments from this specific plant without testing individual batches. The strict enforcement action followed an extensive inspection that uncovered critical data integrity gaps and facility maintenance failures. Most notably, the US drug regulator’s report flagged instances where manufacturing records were allegedly falsified to hide shared equipment usage across multiple products, alongside highly unsanitary warehouse conditions that included the presence of a live bird and bird droppings near packaging materials.
In response to the mounting regulatory scrutiny, Dabur India has actively sought to soothe nervous investors by clarifying that the operational and financial impact of the order remains highly insulated. The company emphasized that the import alert strictly covers private-label over-the-counter products destined for the US market, which generate an entirely insignificant portion of its consolidated revenue. Management confirmed that the Silvassa plant remains fully operational, that its vast network of domestic consumer goods is completely unaffected, and that independent third-party testing has verified no product quality defects. While Dabur is aggressively engaging with US authorities by deploying a comprehensive corrective and preventive action plan to fix the identified infrastructure gaps, the serious nature of the record-keeping violations could prolong the remediation timeline. Investors are maintaining a highly cautious stance, keeping the stock under noticeable pressure as the company navigates this complex compliance hurdle
